Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on February 6, 2017, covering events occurring on February 3, 2017. The filing details a material definitive agreement for a private placement of common stock and the resolution of a Nasdaq listing compliance issue.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of 950,000 shares of common stock via Securities Purchase Agreement.
- Purchase Price: $3.50 per share.
- Gross Proceeds: Approximately $3.3 million.
- Net Proceeds: Approximately $3.0 million (after deducting placement agent fees and estimated offering expenses).
- Placement Agent Fees: 6.5% of gross proceeds plus up to $75,000 in non-accountable expenses.
- Expected Closing Date: February 8, 2017.
- Use of Proceeds: Payment of monthly principal and interest on an outstanding term loan, working capital, and general corporate purposes.
Material Changes and Regulatory Status
The filing reports the resolution of a Nasdaq listing deficiency. On December 20, 2016, the Company received notice that its stock price had fallen below the $1.00 minimum bid price requirement for 30 consecutive business days. On February 3, 2017, Nasdaq confirmed that the closing bid price had been at least $1.00 for 10 consecutive business days (January 20 to February 2, 2017), thereby restoring compliance and closing the matter.
Guidance, Outlook, and Risks
The Company intends to utilize the net proceeds to service its outstanding term loan debt, indicating a focus on liquidity management. The filing includes standard disclaimers that representations and warranties in the Purchase Agreement are for risk allocation between parties and should not be relied upon as statements of fact regarding the Company's condition. No specific forward-looking financial guidance or revenue projections were provided in this filing.
Key Facts for Investor Verification
- Verify the actual closing of the transaction on or around February 8, 2017, and the receipt of net proceeds.
- Confirm the specific terms and maturity of the "outstanding term loan" referenced for repayment.
- Monitor the stock price to ensure continued compliance with Nasdaq listing rules following the recent restoration.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or registration rights granted to investors.